Literature DB >> 21722806

Immunophenotypic pattern of myeloid populations by flow cytometry analysis.

Wojciech Gorczyca1, Zhong-Yi Sun, William Cronin, Xiaoyu Li, Sophal Mau, Sorina Tugulea.   

Abstract

We present our experience with immunophenotypic characteristics of benign and malignant myeloid populations, with emphasis on differential diagnosis especially between eosinophils, dysplastic granulocytes, neoplastic promyelocytes, and monocytes. Eosinophils are characterized by bright CD45, high side scatter (SSC), very low forward scatter (FSC), positive CD11b, CD11c, CD13, CD15, and CD33. They are negative for CD10, CD14, CD16, CD56, CD64, and HLA-DR. Mature monocytes are positive for CD11b, CD11c, CD13, CD14, CD33, and CD64, and may express CD2 and CD4. Blasts in acute myeloid leukemias (AML) with minimal differentiation have low SSC and moderate CD45 expression and are positive for CD34, CD117, CD13, HLA-DR, and CD33 and may be positive for TdT, CD4, and CD11c. In acute promyelocytic leukemia (APL), four FC patterns can be recognized. The majority of cases represented classical (hypergranular) APL and were characterized by high SSC, positive CD117, usually negative CD34, heterogeneous CD13, and bright CD33 (pattern 1). The second most common type, corresponding to hypogranular (microgranular) variant of APL, differed from classical APL by low SSC and frequent coexpression of CD2 and CD34 (pattern 2). Rare cases of APL (pattern3) showed mixture of neoplastic cells (SSC(low)/CD2(+)/CD13(+)/CD33(+)/CD34(+)/CD117(+)) and prominent population of benign granulocytes/maturing myeloid precursors (SSC(high)/CD10(+/-)/CD16(+/()/CD117(()). One case showed two APL populations, one with hypogranular and one with hypergranular characteristics (pattern 4). Detailed phenotypic characteristics of neoplastic monocytes and dysplastic granulocytes with their differential diagnosis are also presented.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21722806     DOI: 10.1016/B978-0-12-385493-3.00010-3

Source DB:  PubMed          Journal:  Methods Cell Biol        ISSN: 0091-679X            Impact factor:   1.441


  40 in total

1.  Authors' reply to 'Granulocytic myeloid-derived suppressor cells in peripheral blood of patients with cutaneous melanoma'.

Authors:  Ivan Stanojevic; Mirjana Djukic; Danilo Vojvodic
Journal:  Int Immunol       Date:  2015-12-29       Impact factor: 4.823

2.  An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte expansion and tuberculosis severity in humans.

Authors:  Murilo Delgobo; Daniel Agb Mendes; Edgar Kozlova; Edroaldo Lummertz Rocha; Gabriela F Rodrigues-Luiz; Lucas Mascarin; Greicy Dias; Daniel O Patrício; Tim Dierckx; Maíra A Bicca; Gaëlle Bretton; Yonne Karoline Tenório de Menezes; Márick R Starick; Darcita Rovaris; Joanita Del Moral; Daniel S Mansur; Johan Van Weyenbergh; André Báfica
Journal:  Elife       Date:  2019-10-22       Impact factor: 8.140

3.  Heparanase is required for activation and function of macrophages.

Authors:  Lilach Gutter-Kapon; Dror Alishekevitz; Yuval Shaked; Jin-Ping Li; Ami Aronheim; Neta Ilan; Israel Vlodavsky
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-14       Impact factor: 11.205

4.  Propofol Sedation Exacerbates Kidney Pathology and Dissemination of Bacteria during Staphylococcus aureus Bloodstream Infections.

Authors:  Lavanya Visvabharathy; Nancy E Freitag
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

5.  Changes in Gene Expression and Metabolism in the Testes of the Rat following Spinal Cord Injury.

Authors:  Ryan D Fortune; Raymond J Grill; Christine Beeton; Mark Tanner; Redwan Huq; David S Loose
Journal:  J Neurotrauma       Date:  2016-12-02       Impact factor: 5.269

6.  Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia.

Authors:  Hua Lu; Quan Zhou; Vishal Deshmukh; Hardeep Phull; Jennifer Ma; Virginie Tardif; Rahul R Naik; Claire Bouvard; Yong Zhang; Seihyun Choi; Brian R Lawson; Shoutian Zhu; Chan Hyuk Kim; Peter G Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2014-07-23       Impact factor: 15.336

Review 7.  Eosinophil and mast cell Siglecs: From biology to drug target.

Authors:  Jeremy A O'Sullivan; Alan T Chang; Bradford A Youngblood; Bruce S Bochner
Journal:  J Leukoc Biol       Date:  2020-01-22       Impact factor: 4.962

8.  Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury.

Authors:  Hadar Arien-Zakay; Galit Gincberg; Arnon Nagler; Gadi Cohen; Sigal Liraz-Zaltsman; Victoria Trembovler; Alexander G Alexandrovich; Ilan Matok; Hanan Galski; Uriel Elchalal; Peter I Lelkes; Philip Lazarovici; Esther Shohami
Journal:  J Neurotrauma       Date:  2014-07-14       Impact factor: 5.269

9.  An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells.

Authors:  Sheena C Kerr; Jeanmarie R Gonzalez; Julia Schanin; Michael C Peters; Bart N Lambrecht; Emily C Brock; Annabelle Charbit; K M Ansel; Bradford A Youngblood; John V Fahy
Journal:  Clin Exp Allergy       Date:  2020-07-08       Impact factor: 5.018

Review 10.  "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?

Authors:  Xueyan Chen; Jonathan R Fromm; Kikkeri N Naresh
Journal:  Leukemia       Date:  2022-01-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.